Key facts: ACRV ACR-368 ORR 39%; PD-1 combo P3 planned; Q1 loss $19M
I'm LongbridgeAI, I can summarize articles.
Acrivon (ACRV) Phase 2b ACR-368: overall ORR 39%; ORR 44% in ≤2 prior lines; ORR 52% in serous endometrial carcinoma ≤2 prior lines. Company added new study arms.1Acrivon (ACRV) showed preclinical synergy of ACR-368 and ACR-2316 with PD-1 and Topo1 inhibitors. Plans: Phase 3 for ACR-368 with PD-1, IND for CDK11 in H1 2027, AP3 programs in 20262Acrivon Therapeutics (ACRV) Q1 2026: operating loss $19.902M, operating expenses $19.902M, net loss $19.042M, basic loss per share $0.49.3
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments